India Biosimilar Market Growth & Outlook Report 2034
India Biosimilar Market Growth & Outlook Report 2034
Blog Article
India Biosimilar Market Overview
The India biosimilar market is emerging as a key segment within the healthcare industry, driven by increasing incidences of chronic illnesses, including cancer, diabetes, and autoimmune disorders. Biosimilars, which are highly similar to approved biologic drugs, offer cost-effective alternatives and enhance patient access to advanced therapies. The country's robust pharmaceutical infrastructure, supportive regulatory environment, and affordability of biosimilars contribute significantly to the market's expansion. India is positioned to become a global biosimilar hub, catering not only to domestic demand but also to international markets.
India Biosimilar Market Size and Share
As of 2024, the India biosimilar market was valued at INR 4.37 billion and is projected to grow at a CAGR of 14.20% to reach INR 16.49 billion by 2034. Growth is driven by rising demand, R&D investments, and government support for affordable biologics. Check out Expert Market Research's India Biosimilar Market.
India Biosimilar Market Trends
The first prominent trend is the rising acceptance of biosimilars in oncology and autoimmune diseases. With the expiration of patents for several blockbuster biologics, biosimilars are becoming increasingly available, enabling patients to access essential cancer and autoimmune treatments at reduced costs.
Secondly, increased partnerships between Indian pharmaceutical companies and global biotechnology firms are driving innovation and market penetration. These collaborations facilitate technology transfer, improved manufacturing capacities, and global regulatory approvals, boosting India’s biosimilar export potential.
Another trend is the emphasis on R&D and clinical trials tailored for biosimilars. Indian companies are increasingly investing in advanced biotechnology platforms, pharmacovigilance, and real-world evidence generation to ensure the efficacy and safety of biosimilar drugs.
Finally, growing awareness and education about biosimilars among healthcare professionals and patients are creating a more favorable adoption environment. Government campaigns and industry-led initiatives are enhancing trust and confidence in biosimilar therapies across diverse demographic groups.
India Biosimilar Market Analysis
Rising healthcare expenditures and the economic burden of chronic diseases are accelerating demand for cost-effective biosimilar therapies in India.
Regulatory support from bodies like CDSCO and the Department of Biotechnology (DBT) has streamlined biosimilar approval pathways, encouraging market entry.
The Indian pharmaceutical industry's capacity for large-scale manufacturing makes it well-suited to meet both domestic and international biosimilar demands.
Furthermore, the increasing involvement of Contract Research Organizations (CROs) in biosimilar development is accelerating clinical research and reducing time-to-market.
The Future of India Biosimilar Market Is Now
Position your business for success with global insights and data-driven forecasts—get your free copy today.
India Biosimilar Market Segmentation
Breakup by Product Class
Monoclonal antibodies dominate the product class segment due to their effectiveness in oncology and autoimmune treatments. Their patent expiries open pathways for biosimilar introductions. Recombinant hormones like insulin and growth hormones are gaining traction owing to rising diabetes and growth disorders. Immunomodulators are used to regulate immune responses, especially in autoimmune diseases. Anti-inflammatory agents are increasingly in demand to treat arthritis and similar disorders. Other product classes include biosimilars targeting fertility, ophthalmic, and cardiovascular conditions, which are gradually expanding due to diverse therapeutic requirements.
Breakup by Manufacturing Type
In-house manufacturing continues to be the primary mode of production for many leading Indian biosimilar manufacturers. It allows greater quality control, proprietary technology retention, and reduced long-term costs. On the other hand, contract manufacturing is growing, especially among mid-sized companies that lack extensive production infrastructure. It offers flexibility, reduced capital expenditure, and scalability benefits, making it suitable for rapid market responses and global exports.
Breakup by Applications
Biosimilars are widely applied in blood disorders such as anemia and hemophilia due to the need for cost-effective biologics. Growth hormonal deficiency treatments using recombinant biosimilars are expanding with improved pediatric healthcare awareness. Chronic and autoimmune disorders, including rheumatoid arthritis and psoriasis, account for a substantial share, given their long-term treatment needs. Oncology remains one of the most lucrative segments, with biosimilars used in breast cancer, colorectal cancer, and more. Other applications include fertility treatments, ophthalmic conditions, and supportive care for various chronic illnesses.
Breakup by Region
North America: North America is a key export destination for Indian biosimilars, supported by regulatory harmonization and FDA approvals. The region offers lucrative opportunities for Indian companies looking to commercialize cost-efficient therapies.
Europe: The European biosimilar market has matured with well-established frameworks. Indian manufacturers benefit from clear regulatory pathways and rising biosimilar adoption in countries like the UK, Germany, and France.
Asia Pacific: Asia Pacific, including India, is experiencing the fastest growth in biosimilar consumption. Population size, chronic disease prevalence, and favorable government support make it a central market for development and distribution.
Latin America, Middle East, and Africa: These regions are increasingly being targeted by Indian companies due to unmet medical needs, high biologic costs, and expanding healthcare infrastructure. They offer a promising frontier for biosimilar adoption.
India Biosimilar Market Growth
The India biosimilar market is set to grow rapidly due to multiple catalysts. The growing burden of chronic diseases like cancer, diabetes, and autoimmune conditions demands affordable long-term therapies, which biosimilars effectively provide. Patent expirations of major biologic drugs allow market entry for Indian manufacturers. Government initiatives like "Atmanirbhar Bharat" and incentives under the PLI (Production-Linked Incentive) scheme boost domestic biotech capabilities. Additionally, enhanced awareness among patients and prescribers, coupled with greater insurance coverage for biosimilar therapies, is expected to create sustained demand in the coming years.
Recent Developments & Challenges
- Biocon Biologics received approval from the UK MHRA for its Bevacizumab biosimilar, marking a significant step toward European penetration.
- Dr. Reddy’s Laboratories launched its adalimumab biosimilar in India, expanding treatment access for rheumatoid arthritis patients.
- The Indian government unveiled a new draft policy for biosimilars under the CDSCO, aiming to simplify and accelerate approvals.
- Lack of biosimilar education among rural physicians and patients remains a key challenge, hindering adoption outside metro cities.
Key Players
Biocon Limited
Biocon is a pioneer in the Indian biosimilar industry with a diverse portfolio covering oncology, diabetes, and autoimmune diseases. Its biologics arm, Biocon Biologics, has achieved global recognition through partnerships with Mylan (now Viatris) and approvals in major markets like the US and EU. The company emphasizes innovation, affordability, and regulatory compliance.
Dr. Reddy’s Laboratories
Dr. Reddy's has significantly expanded its biosimilar portfolio, especially in areas like autoimmune and oncology. The company invests heavily in R&D and manufacturing and has secured multiple approvals in developed and emerging markets. Its biosimilars are known for their affordability and clinical efficacy.
Intas Pharmaceuticals Ltd.
Intas is a leading biosimilar producer, particularly noted for its strong presence in the European Union. Its product line includes filgrastim, pegfilgrastim, and rituximab biosimilars. Intas focuses on continuous innovation, cost-effective production, and expanding global outreach.
copyright Inc.
Though a multinational giant, copyright plays a vital role in biosimilar growth in India through partnerships and licensing deals. The company supports biosimilar education and accessibility initiatives, helping to strengthen the sector's credibility and adoption rates in urban centers.
Other notable companies include Eli Lilly and Company, Celltrion Healthcare, Viatris Inc., Novartis AG, Samsung Bioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., LG Life Sciences Inc., Amgen Inc., Coherus Biosciences Inc., and Biocad.
FAQs
Q1. What are biosimilars?
Biosimilars are biologic medical products highly similar to already approved biologic drugs, with no clinically meaningful differences in safety, purity, and efficacy.
Q2. Why is the biosimilar market growing in India?
India's biosimilar market is growing due to the rising prevalence of chronic diseases, cost advantages, government support, and increased patient access to biologic therapies.
Q3. Which are the top biosimilar companies in India?
Top companies include Biocon, Dr. Reddy’s Laboratories, Intas Pharmaceuticals, and Sun Pharma, among others.
Q4. What are the challenges facing the biosimilar market in India?
Challenges include limited rural access, low awareness among healthcare professionals, and complex regulatory pathways.
Q5. How are biosimilars regulated in India?
Biosimilars in India are regulated by the Central Drugs Standard Control Organization (CDSCO) and must follow the Guidelines on Similar Biologics issued by CDSCO and the Department of Biotechnology (DBT).
View More Reports
Nanopore Sequencing Market
Osteoporosis Drug Pipeline Analysis Report
India Disposable Medical Gloves Market
CDMO Market Size
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com Report this page